Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer

(MedPage Today) -- SEOUL, South Korea -- Combining the novel anti-TIGIT monoclonal antibody tiragolumab with atezolizumab (Tecentriq) to treat PD-L1-positive recurrent cervical cancer didn't improve overall response rate (ORR) in the phase II...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news